Clinical trials
Advanced or Metastatic Non-small Cell Lung Cancer clinical trials
Below are recruiting advanced or metastatic non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 5,671 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05655312RecruitingPhase 1/Phase 2
Targeted radiation melanoma treatment with or without nivolumab
This early-stage study tests whether a targeted radioactive drug can shrink advanced melanoma, either alone or along with nivolumab (an immune-activating medicine). You may be eligible if your melanoma shows a specific target on scan imaging and has progressed despite prior melanoma treatments.
Orange, CaliforniaAges 18–90 - NCT05694715RecruitingPhase 1
Test combo treatment for cancers with DNA repair gene mutations
This Phase 1 study tests a combination of medicines (including niraparib and irinotecan) for advanced solid tumors that have specific DNA repair gene changes, such as BRCA1/2 or related defects. It aims to see whether the treatment can shrink tumors and is safe enough to continue studying.
San Francisco, CaliforniaAges 18 years+ - NCT05707819Recruiting
Sintilimab plus chemoradiotherapy for high-risk nasopharyngeal cancer
This trial tests whether adding sintilimab (an immune treatment) to standard chemoradiotherapy can improve outcomes for people with high-risk, locally advanced nasopharyngeal (throat) cancer. It may help your immune system work better against the cancer alongside radiation and chemotherapy.
Nanning, GuangxiAges 18–70 - NCT05717738Recruiting
Immunotherapy plus targeted drugs after TACE for liver cancer
This trial tests a combination of blood-vessel–targeting medicine and immunotherapy after a liver-directed treatment called TACE for advanced hepatocellular carcinoma (HCC). It aims to control tumor growth when surgery or ablation isn’t suitable, and to see if this “conversion therapy” helps patients do better than standard pathways.
Quanzhou, FujianAges 18 years+ - NCT05727904RecruitingPhase 3
New immunotherapy for advanced melanoma, with or without lifileucel
This trial studies whether adding lifileucel (a patient-specific immune-cell treatment) to pembrolizumab works better than pembrolizumab alone. It’s for people with untreated advanced melanoma that cannot be removed by surgery.
Birmingham, AlabamaAges 18–70 - NCT05727787Recruiting
Radiation trial for liver cancer that cannot be removed
This Phase I study tests a specific radiation approach (vGRID SBRT) for hepatocellular carcinoma (and some mixed types) that is advanced and cannot be cured with surgery or transplant. It aims to control tumors while staying within safety limits for the liver and nearby organs.
Kansas City, KansasAges 18 years+ - NCT05735145RecruitingPhase 3
Chemo plus radiation, then extra chemo for advanced cervical cancer
This Phase 3 study looks at whether adding chemotherapy after standard chemo-radiation can improve outcomes for advanced cervical cancer. You might be eligible if your cancer responded fully to initial treatment and you meet safety and health requirements.
Liuzhou, GuangxiAges 18–75 - NCT05737303RecruitingPhase 3
First-line chemotherapy comparison for advanced ovarian cancer
This Phase 3 trial compares two chemotherapy drug approaches (nab-paclitaxel vs another taxane drug) as the first treatment for advanced ovarian, fallopian tube, or peritoneal cancer. It aims to find which option works better and is tolerated better in people with stage III–IV disease.
Guangzhou, GuangdongAges 18–75 - NCT05752136RecruitingPhase 3
Pre-surgery radiation plus immunotherapy and chemo for rectal cancer
This trial tests whether a short course of radiation before surgery, combined with the immunotherapy drug envafolimab and the chemo regimen CAPEOX, works better for shrinking locally advanced rectal cancer. It is aimed at people whose tumor is not “MMR-deficient” (it is pMMR/MSS), and it asks participants to be able to return for repeated checkups and treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT05767671Recruiting
Breathing tube patients in ICU tested for lung inflammation treatment
This trial studies whether changing immune cells in the lungs (using a procedure called MiniBAL) can improve outcomes in adults who are critically ill and on a breathing tube. It may help doctors better manage acute lung injury by targeting inflammation early in the ICU stay.
Denver, ColoradoAges 18–99 - NCT05768139RecruitingPhase 1/Phase 2
Testing a new targeted drug for advanced solid tumors with PI3Kα mutation
This trial tests tersolisib, a new targeted medicine, in adults with advanced or hard-to-remove solid cancers. It focuses on tumors that have a specific genetic change (PI3Kα mutation) to see how well the treatment works and what side effects it causes.
Los Angeles, CaliforniaAges 18 years+ - NCT05772481Recruiting
PET-MRI scan test for rectal cancer after pre-surgery treatment
This study looks at whether a special scan called PET-MRI can better show how rectal cancer responds to treatment given before surgery. If it works well, it could help doctors plan the right next steps after chemoradiotherapy.
StrasbourgAges 18–75 - NCT05785039RecruitingPhase 2
Study drug for advanced bladder and other solid cancers
This Phase 2 trial tests BL-B01D1 to treat people with advanced or metastatic urothelial (urinary tract) cancer and other solid tumors. You may be eligible if standard treatments are no longer working or are not available, and you can meet safety and cancer-measurement requirements.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05817903RecruitingPhase 2
Nivolumab with or without axitinib after prior nivolumab
This Phase 2 trial studies whether adding axitinib to nivolumab (or giving nivolumab alone) can better control advanced clear-cell kidney cancer after standard initial treatment with nivolumab plus ipilimumab. It may help by extending response or slowing tumor growth while improving how long treatment works.
BresciaAges 18 years+ - NCT05830500RecruitingPhase 4
Anlotinib for advanced medullary thyroid cancer
This trial studies anlotinib in people with advanced or metastatic medullary thyroid cancer that has been getting worse. It aims to see how well the treatment controls the cancer and how safe it is for patients who can’t have curative surgery.
Hefei, AnhuiAges 18–75 - NCT05854823Recruiting
Reduced radiation after surgery for advanced head and neck cancer
This trial looks at whether giving less (de-escalated) radiation after surgery is as effective and safer for people with locally advanced head and neck squamous cell carcinoma who had a strong response to treatment before surgery. If you had no remaining cancer or only very small amounts of cancer left in the surgical specimen, this approach may help reduce side effects while keeping control of the disease.
Zhuhai, GuangdongAges 18–70 - NCT05860361Recruiting
Registry to collect proton therapy data for cancer patients
This study collects high-quality information about people who are planning to receive proton therapy for cancer or other tumors. It does not change your treatment; it helps researchers improve proton therapy for future patients.
MilanAges 18 years+ - NCT05892718RecruitingPhase 1
Testing an immune drug for hard-to-treat cancers
This early-phase study tests HCB101, an immune-targeting drug, to see if it is safe and can shrink certain solid tumors or non-Hodgkin lymphoma. It may help people whose cancer has returned or stopped responding to standard treatments.
Port Saint Lucie, FloridaAges 18 years+ - NCT05898399RecruitingPhase 1/Phase 2
Testing ART6043 for advanced cancers with DNA repair defects
This early-phase study tests ART6043 in people with advanced or metastatic solid tumors, and in some parts with breast cancer plus specific gene changes. The goal is to see how well it works and whether it is safe, sometimes combined with olaparib.
Grand Rapids, MichiganAges 18 years+ - NCT05926726Recruiting
GPC3-targeted CAR-T for advanced liver cancer
This trial tests a custom immune-cell treatment (CAR-T) that targets a marker called GPC3 in people with advanced hepatocellular carcinoma (a type of liver cancer). It’s for cases where standard treatments have not worked well, and the goal is to shrink tumors and improve outcomes.
ShanghaiAges 18–75 - NCT05941338RecruitingPhase 2
Tirelizumab plus chemotherapy before head and neck surgery
This Phase 2 trial tests tirelizumab combined with two chemotherapy medicines before surgery for certain head and neck squamous cell cancers. It aims to shrink the tumor and improve outcomes after the operation.
Guangzhou, GuangdongAges 18–65 - NCT05947695Recruiting
Nurse-led comfort and survivorship care for advanced cancer
This study looks at whether a specialized nurse-led care plan soon after diagnosis/treatment helps people living with advanced (metastatic) cancer. It focuses on patients expected to do better than average based on certain prognosis factors.
West Islip, New YorkAges 21 years+ - NCT05965856RecruitingPhase 2
Testing two antibody medicines for advanced bladder and other cancers
This Phase 2 trial studies whether the study medicines SI-B003 alone or together with BL-B01D1 plus SI-B003 can shrink or control advanced cancers that have not responded to standard treatment (or where standard treatment isn’t possible). It also looks at safety and how well the treatment works in people whose cancer can be measured on scans.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05969041RecruitingPhase 1
Early-phase drug trial for advanced epithelial cancers
This Phase 1 study tests a new drug (MT-302) in adults with advanced or metastatic epithelial cancers that have worsened or stopped responding to standard treatment. The goal is to see how the drug works and whether it is safe for people with limited options.
Darlinghurst, New South WalesAges 18 years+
Hear when a new Advanced or Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic non-small cell lung cancer?
- Yes. Clin2 currently lists 5,671 recruiting advanced or metastatic non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Locally Advanced Non-Small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.